Y. Zhang

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

Yi‐Long Wu, Caicun Zhou, Chong Kin Liam et al. · Annals of Oncology · 2015 · 726 citations

Medicine, Phase Iii, Pathology +7

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

Favorable Response to Human Adipose Tissue-Derived Mesenchymal Stem Cells in Steroid-Refractory Acute Graft-Versus-Host Disease

Baijun Fang, Yaqi Song, Lianming Liao et al. · Transplantation Proceedings · 2007 · 234 citations

Regenerative Medicine, Tissue Engineering, Cell Therapy +11

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6

Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients—Based on a hospital study in China

Zhengbo Song, Hong Zhu, Ziwei Guo et al. · European Journal of Surgical Oncology · 2013 · 71 citations

Prognostic Evaluation, Prognostic Biomarkers, Medicine +10